JGACX
Price
$32.24
Change
-$0.01 (-0.03%)
Updated
Sep 5 closing price
Net Assets
22.92B
RGEBX
Price
$82.44
Change
+$0.19 (+0.23%)
Updated
Sep 5 closing price
Net Assets
331.65B
Interact to see
Advertisement

JGACX vs RGEBX

Header iconJGACX vs RGEBX Comparison
Open Charts JGACX vs RGEBXBanner chart's image
JPMorgan Growth Advantage C
Price$32.24
Change-$0.01 (-0.03%)
VolumeN/A
Net Assets22.92B
American Funds Growth Fund of Amer R2E
Price$82.44
Change+$0.19 (+0.23%)
VolumeN/A
Net Assets331.65B
JGACX vs RGEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
JGACX vs. RGEBX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JGACX is a Buy and RGEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 332B vs. JGACX (22.9B). JGACX (0.00) and RGEBX (0.00) have matching dividends . JGACX was incepted earlier than RGEBX: JGACX (19 years) vs RGEBX (11 years). JGACX (1.59) is less costly to investors than RGEBX (1.09). JGACX is a more actively managed with annual turnover of: 28.00 vs. RGEBX (25.00). RGEBX has a lower initial minimum investment than JGACX: RGEBX (250) vs JGACX (1000). RGEBX annual gain was more profitable for investors over the last year : 17.32 vs. JGACX (14.73). RGEBX return over 5 years is better than : 38.39 vs. JGACX (31.74).
JGACXRGEBXJGACX / RGEBX
Total Expense Ratio1.491.09137%
Annual Report Gross Expense Ratio1.591.09146%
Fund Existence19 years11 years-
Gain YTD10.86315.13272%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets22.9B332B7%
Annual Yield % from dividends0.000.00-
Returns for 1 year14.7317.3285%
Returns for 3 years71.4557.24125%
Returns for 5 years31.7438.3983%
Returns for 10 years131.6891.00145%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARTV3.610.50
+16.08%
Artiva Biotherapeutics Inc
ARCT17.851.09
+6.50%
Arcturus Therapeutics Holdings
MANH215.315.45
+2.60%
Manhattan Associates
TRMD23.020.25
+1.10%
TORM plc
INDP3.30-1.31
-28.35%
Indaptus Therapeutics Inc